Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.
2.

Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients.

Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S.

Breast Cancer Res Treat. 2011 Aug;128(3):633-41. doi: 10.1007/s10549-010-1145-z.

PMID:
20803240
3.

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.

Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, Chuang EY.

PLoS One. 2012;7(9):e45831. doi: 10.1371/journal.pone.0045831.

4.

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.

Bertucci F, Borie N, Roche H, Bachelot T, Le Doussal JM, Macgrogan G, Debono S, Martinec A, Treilleux I, Finetti P, Esterni B, Extra JM, Geneve J, Hermitte F, Chabannon C, Jacquemier J, Martin AL, Longy M, Maraninchi D, Fert V, Birnbaum D, Viens P.

Breast Cancer Res Treat. 2011 Jun;127(2):363-73. doi: 10.1007/s10549-010-1003-z.

PMID:
20585850
5.

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.

Clin Cancer Res. 2005 May 1;11(9):3315-9.

6.

Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.

Specht K, Harbeck N, Smida J, Annecke K, Reich U, Naehrig J, Langer R, Mages J, Busch R, Kruse E, Klein-Hitpass L, Schmitt M, Kiechle M, Hoefler H.

Breast Cancer Res Treat. 2009 Nov;118(1):45-56. doi: 10.1007/s10549-008-0207-y.

PMID:
18925433
7.

A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM.

Clin Cancer Res. 2008 Mar 15;14(6):1744-52. doi: 10.1158/1078-0432.CCR-07-1833.

8.

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA, Chetty U.

Breast Cancer Res. 2010;12(4):R47. doi: 10.1186/bcr2604.

9.

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium..

Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2.

PMID:
18661261
10.

A gene-expression signature as a predictor of survival in breast cancer.

van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R.

N Engl J Med. 2002 Dec 19;347(25):1999-2009.

11.

Accuracy validation of adjuvant! online in Taiwanese breast cancer patients--a 10-year analysis.

Yao-Lung K, Dar-Ren C, Tsai-Wang C.

BMC Med Inform Decis Mak. 2012 Sep 17;12:108. doi: 10.1186/1472-6947-12-108.

12.

Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.

Kao KJ, Chang KM, Hsu HC, Huang AT.

BMC Cancer. 2011 Apr 18;11:143. doi: 10.1186/1471-2407-11-143.

13.

A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.

Kerr DA 2nd, Wittliff JL.

Horm Cancer. 2011 Oct;2(5):261-71. doi: 10.1007/s12672-011-0080-8.

PMID:
21826535
14.

Population-based molecular prognosis of breast cancer by transcriptional profiling.

Ma Y, Qian Y, Wei L, Abraham J, Shi X, Castranova V, Harner EJ, Flynn DC, Guo L.

Clin Cancer Res. 2007 Apr 1;13(7):2014-22.

15.

Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer.

Karlsson E, Delle U, Danielsson A, Olsson B, Abel F, Karlsson P, Helou K.

BMC Cancer. 2008 Sep 8;8:254. doi: 10.1186/1471-2407-8-254.

16.

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z.

Breast Cancer Res Treat. 2010 Oct;123(3):725-31. doi: 10.1007/s10549-009-0674-9.

17.

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ.

Breast Cancer Res Treat. 2010 Apr;120(3):655-61. doi: 10.1007/s10549-010-0814-2.

PMID:
20204499
18.

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C; TRANSBIG Consortium..

Clin Cancer Res. 2007 Jun 1;13(11):3207-14.

19.

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH.

Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072.

20.

Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.

Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, et al.

Clin Cancer Res. 1995 Feb;1(2):189-98.

Items per page

Supplemental Content

Support Center